Drug intelligence / Profile preview

CPV-161

Development stage: Preclinical
Lead developer: University of Puerto Rico
Modality: Small Molecules

Overview

CPV-161 is a preclinical cyclic thiosulfinate derivative designed as an inhibitor of thioredoxin reductase (TrxR). Developed by researchers at the University of Puerto Rico, CPV-161 targets the active-site cysteine residues of TrxR to disrupt cellular redox homeostasis, induce oxidative stress, and inhibit cell proliferation. In preclinical in vitro screenings, CPV-161 demonstrated significant cytotoxic activity against a panel of breast cancer cell lines, including MCF-7, ZR-75-1, BT-20, MDA-MB-468, SkBr-3, BT-474, and MDA-MB-231, reducing cell growth by 74% to 94%.

Targets

TXNRD1 (Thioredoxin reductase 1)

Beyond the preview

Go deeper on CPV-161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPV-161.

Explore the full profile